Gossamer Bio shares surge 10.36% intraday as analysts boost price target and anticipate key clinical data in 2026.

Gossamer Bio surged 10.36% intraday as analysts upgraded the stock ahead of critical clinical milestones. The firm’s consensus price target rose to $9.50, reflecting heightened optimism about seralutinib’s prospects, particularly with Cantor Fitzgerald maintaining an Overweight rating and highlighting the drug’s potential ahead of the February 2026 PROSERA trial data readout. The stock’s rally aligns with increased analyst confidence in Gossamer Bio’s ability to execute on its clinical roadmap, despite bearish concerns about valuation risks. Upcoming presentations at the European Respiratory Society Congress 2025 and a global partnership with Chiesi Group further bolstered investor sentiment, underscoring seralutinib’s novel mechanism in targeting idiopathic pulmonary fibrosis. The move reflects anticipation of late-stage trial success and expanded market opportunities.